Burning Rock

In Brief This Week: Burning Rock, Ainos, Helio Health

360Dx Top 30 Inches Up in May After April Plummet

Genetron, Burning Rock, Others Receive CE Marks for Cancer, COVID-19 Tests

Burning Rock Biotech Q1 Revenues up 27 Percent

360Dx Top 30 Drops 11 Percent in April, Following Broader Market Trends

360Dx Top 30 Falls Slightly in March

Burning Rock Q4 Revenues up 12 Percent

Burning Rock Secures Lung Cancer NGS Test Regulatory Approval in China

360Dx Index Rises 20 Percent in 2021

360Dx Index Grows 4 Percent in December Alongside Broader Markets

360Dx Index Follows Larger Market Trends, Drops 4 Percent in November

Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal

Burning Rock Q3 Revenues Inch up 2 Percent

360Dx Index Maintains Steady Ascent, Increasing 3 Percent in August

Burning Rock Q2 Revenues up 19 Percent

Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib

360Dx Index Continues Growth in July, Increasing 5 Percent